Weight Loss Protocol
Semaglutide + Tesamorelin
Comprehensive weight loss with targeted visceral fat reduction
Overview
Combines an FDA-approved GLP-1 receptor agonist with an FDA-approved growth hormone releasing factor. Semaglutide reduces appetite and improves glycemic control through incretin pathways, while Tesamorelin specifically targets visceral adipose tissue through GH-mediated lipolysis. Together they address both caloric intake reduction and targeted fat mobilization.
Component Peptides
GLP-1 receptor agonist — reduces appetite, slows gastric emptying, improves insulin sensitivity, FDA-approved for weight management (Wegovy)
GHRH analog — FDA-approved for reducing visceral fat in HIV-associated lipodystrophy, stimulates natural GH release targeting abdominal fat
Expected Timeline
Appetite reduction within 1-2 weeks of starting semaglutide (during titration). Significant weight loss at 8-12 weeks. Visceral fat reduction measurable by 12-16 weeks with tesamorelin. Optimal results at 6-12 months.
Safety Notes
- Semaglutide requires slow dose titration (start 0.25mg, increase monthly) to minimize GI side effects
- Common semaglutide side effects: nausea, vomiting, diarrhea, constipation (usually transient)
- Tesamorelin may cause fluid retention, joint pain, and glucose elevation
- Risk of gallbladder disease with rapid weight loss — monitor for symptoms
- Must be prescribed and monitored by a physician
- Semaglutide carries a boxed warning for medullary thyroid carcinoma risk (based on rodent studies)
Bloodwork Recommendations
- Fasting glucose, HbA1c, and fasting insulin
- Comprehensive metabolic panel including liver function
- Lipid panel (total cholesterol, LDL, HDL, triglycerides)
- IGF-1 levels (for tesamorelin monitoring)
- Thyroid panel (TSH, free T4)
- Amylase and lipase (pancreatic function)
- Gallbladder ultrasound if symptomatic
Contraindications
- Personal or family history of medullary thyroid carcinoma or MEN 2 syndrome
- Pancreatitis (active or history)
- Active pituitary pathology (for tesamorelin)
- Pregnancy or breastfeeding (teratogenic risk)
- Type 1 diabetes
- Severe gastroparesis
Evidence Assessment
Both peptides are individually FDA-approved with robust clinical trial data. Semaglutide (as Wegovy) showed 15-17% body weight reduction in the STEP trials. Tesamorelin (as Egrifta) demonstrated significant visceral fat reduction in Phase III trials. The combination has not been studied in an RCT, but both are prescribed by physicians and mechanistically complementary.
References
- Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." N Engl J Med. 2021;384(11):989-1002.
- Falutz J, et al. "Effects of tesamorelin on body composition and metabolic parameters in HIV-infected patients." J Clin Endocrinol Metab. 2010;95(3):1103-1115.
- Stanley TL, et al. "Effects of tesamorelin on non-alcoholic fatty liver disease." Lancet HIV. 2019;6(6):e356-e365.
Research Disclaimer: The information on this page is for educational purposes only and does not constitute medical advice. All products referenced are for in vitro laboratory research use only. Consult a qualified healthcare professional before beginning any research protocol.